WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
Content
Overview
Pomalidomide is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include .
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Pomalidomide FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Pomalidomide in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Pomalidomide in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Pomalidomide in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Pomalidomide in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Pomalidomide in pediatric patients.
Contraindications
Warnings
ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
Content
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Pomalidomide in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Pomalidomide in the drug label.
Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pomalidomide in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Pomalidomide during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Pomalidomide with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Pomalidomide with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Pomalidomide with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Pomalidomide with respect to specific gender populations.
Race
There is no FDA guidance on the use of Pomalidomide with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Pomalidomide in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Pomalidomide in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Pomalidomide in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Pomalidomide in patients who are immunocompromised.
Administration and Monitoring
Administration
Oral
Intravenous
Monitoring
There is limited information regarding Monitoring of Pomalidomide in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Pomalidomide in the drug label.
Overdosage
There is limited information regarding Pomalidomide overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Pomalidomide Pharmacology in the drug label.